Rapport Therapeutics, Inc.
RAPP
$11.38
$0.767.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.69% | 19.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.69% | 4.04% | |||
| Operating Income | -8.69% | -4.04% | |||
| Income Before Tax | -13.93% | 3.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.93% | 3.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.93% | 3.22% | |||
| EBIT | -8.69% | -4.04% | |||
| EBITDA | -8.59% | -4.03% | |||
| EPS Basic | -13.24% | 70.39% | |||
| Normalized Basic EPS | -13.23% | 70.38% | |||
| EPS Diluted | -13.24% | 70.39% | |||
| Normalized Diluted EPS | -13.23% | 70.38% | |||
| Average Basic Shares Outstanding | 0.61% | 226.78% | |||
| Average Diluted Shares Outstanding | 0.61% | 226.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||